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Given several high-profile recalls in recent 
years of pharmaceuticals by the US Food and 
Drug Administration (FDA), the subject of 
pharmaceutical risk management has become 
increasingly important. Pharmaceutical risk 
management refers to manufacturers creating 
special tools and programs to ensure the safe 
use of certain high risk products. The FDA’s 
Amendments Act (FDAAA) of 2007 prompted the 
Food and Drug Law Institute (FDLI) to publish 
Pharmaceutical Risk Management: Practical 
Applications (2008), a follow up to their 2003 
publication, A Framework for Pharmaceutical Risk 
Management. The 2008 edition is a multi-author 
work written by experienced risk managers who 
have organized risk management programs as 
consultants or industry executives; some are 
alumni of the FDA. It is important to note that  
this is not a second edition of the 2003 book,  
but rather an extension of the research and 
methods presented in the original, with an 
emphasis on practical applications of risk 
management principles. The purpose of this 
publication is to educate pharmaceutical 
companies, consultants, and other drug industry 
stakeholders on the new rules for Risk Evaluation 
and Mitigation strategies (REMS) during pre-  
and post-marketing drug development.
Pharmaceutical Risk Management: Practical 
Applications provides the historical context for all 
of the recent changes in the FDA’s requirements 
for risk management, which culminated with 
the FDAAA of 2007. The authors describe the 
Vioxx® withdrawal from the market and how it 
ultimately compelled the Institute of Medicine 
(IOM) to issue its report, The Future of Drug 
Safety: Promoting and Protecting the Health of 
the Public, which pointed out deficiencies in drug 
safety in the US and made recommendations for 
correcting them. Some of these recommendations 
were incorporated in the FDAAA of 2007, including 
the expanded ability of the FDA to require a 
REMS if the agency deems the strategy would be 
“necessary to ensure that the benefits of the drug 
outweigh the risks of the drug.” The legislation also 
allows the FDA to require a REMS for a previously 
approved drug if it “becomes aware of new safety 
information and makes a determination that such 
a strategy is necessary to ensure that the benefits 
of the drug outweigh its risks.” 
The author/s goes on to address specific elements 
of a REMS or risk management action plan 
(RiskMAP). It details the application of risk 
management to clinical development, regulator 
approval, clinician acceptance, and outcomes 
improvement. Incorporating educational 
interventions into risk management is explored, 
as is evaluating the performance of risk 
management plans. The authors conclude with 
chapters on crisis avoidance and management, 
and the legal implications of risk management. 
An extensive appendix is also provided, including 
three guidance documents on risk management 
published by the FDA in 2005, the FDAAA of 
2007, a list of products with approved REMS in 
effect when the FDAAA was passed, and a March 
2008 draft of the Prescription Drug User Fee Act 
(PDUFA) IV: Drug Safety Five-Year Plan.
This FDLI publication on pharmaceutical risk 
management, when accompanied by A Framework 
for Pharmaceutical Risk Management (2003), acts 
as an excellent primer for individuals devising 
or interpreting a REMS or RiskMAP for the 
FDA, and could also be helpful for devising risk 
management strategies internally or for other 
regulatory agencies. The book provides first-
hand knowledge from a collection of authors 
who have extensive training and experience in 
the field of pharmaceutical risk management. 
Both manufacturers and the FDA hope that 
effective risk management programs will protect 
consumers from future recalls and increase the 
safety of medications in the US.  
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